Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 12 entries
Sorted by: Best Match Show Resources per page
Depletion of ST6GALNACIII retards A549 non-small cell lung cancer cell proliferation by downregulating transferrin receptor protein 1 expression.

Biochemical and biophysical research communications

Jung SY, Lee HK, Kim H, Kim S, Kim JS, Kang JG, Kuh HJ, Yoo JS, Ko JH, Lee JH.
PMID: 34461439
Biochem Biophys Res Commun. 2021 Oct 20;575:78-84. doi: 10.1016/j.bbrc.2021.08.055. Epub 2021 Aug 25.

Alterations in sialylation of terminal residues of glycoproteins have been implicated in forming tumor-associated glycans. ST6GALNAC transfers sialyl moiety to N-acetylgalactosamine residue via α2,6 linkage. Although the oncogenic characteristics of ST6GALNACI or II have been demonstrated in various cancer...

Cite
Jung SY, Lee HK, Kim H, et al. Depletion of ST6GALNACIII retards A549 non-small cell lung cancer cell proliferation by downregulating transferrin receptor protein 1 expression. Biochem Biophys Res Commun. 2021;575:78-84doi: 10.1016/j.bbrc.2021.08.055.
Jung, S. Y., Lee, H. K., Kim, H., Kim, S., Kim, J. S., Kang, J. G., Kuh, H. J., Yoo, J. S., Ko, J. H., & Lee, J. H. (2021). Depletion of ST6GALNACIII retards A549 non-small cell lung cancer cell proliferation by downregulating transferrin receptor protein 1 expression. Biochemical and biophysical research communications, 57578-84. https://doi.org/10.1016/j.bbrc.2021.08.055
Jung, Soon-Young, et al. "Depletion of ST6GALNACIII retards A549 non-small cell lung cancer cell proliferation by downregulating transferrin receptor protein 1 expression." Biochemical and biophysical research communications vol. 575 (2021): 78-84. doi: https://doi.org/10.1016/j.bbrc.2021.08.055
Jung SY, Lee HK, Kim H, Kim S, Kim JS, Kang JG, Kuh HJ, Yoo JS, Ko JH, Lee JH. Depletion of ST6GALNACIII retards A549 non-small cell lung cancer cell proliferation by downregulating transferrin receptor protein 1 expression. Biochem Biophys Res Commun. 2021 Oct 20;575:78-84. doi: 10.1016/j.bbrc.2021.08.055. Epub 2021 Aug 25. PMID: 34461439.
Copy Download .nbib Format: NLM
Effects of ferrous carbamoyl glycine on iron state and absorption in an iron-deficient rat model.

Genes & nutrition

Zhang Y, Sun X, Xie C, Shu X, Oso AO, Ruan Z, Deng ZY, Wu X, Yin Y.
PMID: 26584806
Genes Nutr. 2015 Nov;10(6):54. doi: 10.1007/s12263-015-0504-0. Epub 2015 Nov 19.

An iron-deficient rat model was established and used to determine the effects of different iron sources on iron metabolism and absorption. Iron-deficient rats were assigned to one of three treatment groups, and their diet was supplemented with deionized water...

Cite
Zhang Y, Sun X, Xie C, et al. Effects of ferrous carbamoyl glycine on iron state and absorption in an iron-deficient rat model. Genes Nutr. 2015;10(6):54doi: 10.1007/s12263-015-0504-0.
Zhang, Y., Sun, X., Xie, C., Shu, X., Oso, A. O., Ruan, Z., Deng, Z. Y., Wu, X., & Yin, Y. (2015). Effects of ferrous carbamoyl glycine on iron state and absorption in an iron-deficient rat model. Genes & nutrition, 10(6), 54. https://doi.org/10.1007/s12263-015-0504-0
Zhang, Yuzhe, et al. "Effects of ferrous carbamoyl glycine on iron state and absorption in an iron-deficient rat model." Genes & nutrition vol. 10,6 (2015): 54. doi: https://doi.org/10.1007/s12263-015-0504-0
Zhang Y, Sun X, Xie C, Shu X, Oso AO, Ruan Z, Deng ZY, Wu X, Yin Y. Effects of ferrous carbamoyl glycine on iron state and absorption in an iron-deficient rat model. Genes Nutr. 2015 Nov;10(6):54. doi: 10.1007/s12263-015-0504-0. Epub 2015 Nov 19. PMID: 26584806; PMCID: PMC4653121.
Copy Download .nbib Format: NLM
Activation of NMDA receptors mediated iron accumulation via modulating iron transporters in Parkinson's disease.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology

Xu H, Liu X, Xia J, Yu T, Qu Y, Jiang H, Xie J.
PMID: 29897813
FASEB J. 2018 Jun 13;fj201800060RR. doi: 10.1096/fj.201800060RR. Epub 2018 Jun 13.

Increasing evidence has confirmed that nigral iron accumulation and activation of NMDA receptors (NRs) contribute to the neurodegeneration of dopamine (DA) neurons in Parkinson's disease (PD). Earlier work indicated that activation of NRs participated in iron metabolism in the...

Cite
Xu H, Liu X, Xia J, et al. Activation of NMDA receptors mediated iron accumulation via modulating iron transporters in Parkinson's disease. FASEB J. 2018;fj201800060RRdoi: 10.1096/fj.201800060RR.
Xu, H., Liu, X., Xia, J., Yu, T., Qu, Y., Jiang, H., & Xie, J. (2018). Activation of NMDA receptors mediated iron accumulation via modulating iron transporters in Parkinson's disease. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, fj201800060RR. https://doi.org/10.1096/fj.201800060RR
Xu, Huamin, et al. "Activation of NMDA receptors mediated iron accumulation via modulating iron transporters in Parkinson's disease." FASEB journal : official publication of the Federation of American Societies for Experimental Biology vol. (2018): fj201800060RR. doi: https://doi.org/10.1096/fj.201800060RR
Xu H, Liu X, Xia J, Yu T, Qu Y, Jiang H, Xie J. Activation of NMDA receptors mediated iron accumulation via modulating iron transporters in Parkinson's disease. FASEB J. 2018 Jun 13;fj201800060RR. doi: 10.1096/fj.201800060RR. Epub 2018 Jun 13. PMID: 29897813.
Copy Download .nbib Format: NLM
A novel treatment strategy to prevent Parkinson's disease: focus on iron regulatory protein 1 (IRP1).

The International journal of neuroscience

Berry TM, Moustafa AA.
PMID: 33535005
Int J Neurosci. 2021 May 04;1-10. doi: 10.1080/00207454.2021.1885403. Epub 2021 May 04.

We propose that neural damage in Parkinson's disease (PD) is due to dysregulation of iron utilization rather than to high iron levels per se. Iron deposits are associated with neuronal cell death in substantia nigra (SN) resulting in PD...

Cite
Berry TM, Moustafa AA. A novel treatment strategy to prevent Parkinson's disease: focus on iron regulatory protein 1 (IRP1). Int J Neurosci. 2021;1-10doi: 10.1080/00207454.2021.1885403.
Berry, T. M., & Moustafa, A. A. (2021). A novel treatment strategy to prevent Parkinson's disease: focus on iron regulatory protein 1 (IRP1). The International journal of neuroscience, 1-10. https://doi.org/10.1080/00207454.2021.1885403
Berry, Thomas M, and Moustafa, Ahmed A. "A novel treatment strategy to prevent Parkinson's disease: focus on iron regulatory protein 1 (IRP1)." The International journal of neuroscience vol. (2021): 1-10. doi: https://doi.org/10.1080/00207454.2021.1885403
Berry TM, Moustafa AA. A novel treatment strategy to prevent Parkinson's disease: focus on iron regulatory protein 1 (IRP1). Int J Neurosci. 2021 May 04;1-10. doi: 10.1080/00207454.2021.1885403. Epub 2021 May 04. PMID: 33535005.
Copy Download .nbib Format: NLM
Iron regulatory protein 1 promotes ferroptosis by sustaining cellular iron homeostasis in melanoma.

Oncology letters

Yao F, Cui X, Zhang Y, Bei Z, Wang H, Zhao D, Wang H, Yang Y.
PMID: 34386079
Oncol Lett. 2021 Sep;22(3):657. doi: 10.3892/ol.2021.12918. Epub 2021 Jul 12.

Melanoma, the most aggressive skin cancer, is mainly treated with BRAF inhibitors or immunotheareapy. However, most patients who initially responded to BRAF inhibitors or immunotheareapy become resistant following relapse. Ferroptosis is a form of regulated cell death characterized by...

Cite
Yao F, Cui X, Zhang Y, et al. Iron regulatory protein 1 promotes ferroptosis by sustaining cellular iron homeostasis in melanoma. Oncol Lett. 2021;22(3):657doi: 10.3892/ol.2021.12918.
Yao, F., Cui, X., Zhang, Y., Bei, Z., Wang, H., Zhao, D., Wang, H., & Yang, Y. (2021). Iron regulatory protein 1 promotes ferroptosis by sustaining cellular iron homeostasis in melanoma. Oncology letters, 22(3), 657. https://doi.org/10.3892/ol.2021.12918
Yao, Fengping, et al. "Iron regulatory protein 1 promotes ferroptosis by sustaining cellular iron homeostasis in melanoma." Oncology letters vol. 22,3 (2021): 657. doi: https://doi.org/10.3892/ol.2021.12918
Yao F, Cui X, Zhang Y, Bei Z, Wang H, Zhao D, Wang H, Yang Y. Iron regulatory protein 1 promotes ferroptosis by sustaining cellular iron homeostasis in melanoma. Oncol Lett. 2021 Sep;22(3):657. doi: 10.3892/ol.2021.12918. Epub 2021 Jul 12. PMID: 34386079; PMCID: PMC8299017.
Copy Download .nbib Format: NLM
Brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor inhibit ferrous iron influx via divalent metal transporter 1 and iron regulatory protein 1 regulation in ventral mesencephalic neurons.

Biochimica et biophysica acta

Zhang HY, Song N, Jiang H, Bi MX, Xie JX.
PMID: 25239763
Biochim Biophys Acta. 2014 Dec;1843(12):2967-75. doi: 10.1016/j.bbamcr.2014.09.010. Epub 2014 Sep 16.

Iron accumulation is observed in the substantia nigra of patients with Parkinson's disease. However, it is unknown whether neurotrophic factors, brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) participate in the modulation of neuronal iron metabolism....

Cite
Zhang HY, Song N, Jiang H, et al. Brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor inhibit ferrous iron influx via divalent metal transporter 1 and iron regulatory protein 1 regulation in ventral mesencephalic neurons. Biochim Biophys Acta. 2014;1843(12):2967-75doi: 10.1016/j.bbamcr.2014.09.010.
Zhang, H. Y., Song, N., Jiang, H., Bi, M. X., & Xie, J. X. (2014). Brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor inhibit ferrous iron influx via divalent metal transporter 1 and iron regulatory protein 1 regulation in ventral mesencephalic neurons. Biochimica et biophysica acta, 1843(12), 2967-75. https://doi.org/10.1016/j.bbamcr.2014.09.010
Zhang, Hao-Yun, et al. "Brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor inhibit ferrous iron influx via divalent metal transporter 1 and iron regulatory protein 1 regulation in ventral mesencephalic neurons." Biochimica et biophysica acta vol. 1843,12 (2014): 2967-75. doi: https://doi.org/10.1016/j.bbamcr.2014.09.010
Zhang HY, Song N, Jiang H, Bi MX, Xie JX. Brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor inhibit ferrous iron influx via divalent metal transporter 1 and iron regulatory protein 1 regulation in ventral mesencephalic neurons. Biochim Biophys Acta. 2014 Dec;1843(12):2967-75. doi: 10.1016/j.bbamcr.2014.09.010. Epub 2014 Sep 16. PMID: 25239763.
Copy Download .nbib Format: NLM
Therapeutic inhibition of HIF-2α reverses polycythemia and pulmonary hypertension in murine models of human diseases.

Blood

Ghosh MC, Zhang DL, Ollivierre WH, Noguchi A, Springer DA, Linehan WM, Rouault TA.
PMID: 33512384
Blood. 2021 May 06;137(18):2509-2519. doi: 10.1182/blood.2020009138.

Polycythemia and pulmonary hypertension are 2 human diseases for which better therapies are needed. Upregulation of hypoxia-inducible factor-2α (HIF-2α) and its target genes, erythropoietin (EPO) and endothelin-1, causes polycythemia and pulmonary hypertension in patients with Chuvash polycythemia who are...

Cite
Ghosh MC, Zhang DL, Ollivierre WH, et al. Therapeutic inhibition of HIF-2α reverses polycythemia and pulmonary hypertension in murine models of human diseases. Blood. 2021;137(18):2509-2519doi: 10.1182/blood.2020009138.
Ghosh, M. C., Zhang, D. L., Ollivierre, W. H., Noguchi, A., Springer, D. A., Linehan, W. M., & Rouault, T. A. (2021). Therapeutic inhibition of HIF-2α reverses polycythemia and pulmonary hypertension in murine models of human diseases. Blood, 137(18), 2509-2519. https://doi.org/10.1182/blood.2020009138
Ghosh, Manik C, et al. "Therapeutic inhibition of HIF-2α reverses polycythemia and pulmonary hypertension in murine models of human diseases." Blood vol. 137,18 (2021): 2509-2519. doi: https://doi.org/10.1182/blood.2020009138
Ghosh MC, Zhang DL, Ollivierre WH, Noguchi A, Springer DA, Linehan WM, Rouault TA. Therapeutic inhibition of HIF-2α reverses polycythemia and pulmonary hypertension in murine models of human diseases. Blood. 2021 May 06;137(18):2509-2519. doi: 10.1182/blood.2020009138. PMID: 33512384; PMCID: PMC8109019.
Copy Download .nbib Format: NLM
Posiphen Reduces the Levels of Huntingtin Protein through Translation Suppression.

Pharmaceutics

Chen XQ, Barrero CA, Vasquez-Del Carpio R, Reddy EP, Fecchio C, Merali S, Deglincerti A, Fang C, Rogers J, Maccecchini ML.
PMID: 34959389
Pharmaceutics. 2021 Dec 07;13(12). doi: 10.3390/pharmaceutics13122109.

Posiphen tartrate (Posiphen) is an orally available small molecule that targets a conserved regulatory element in the mRNAs of amyloid precursor protein (APP) and α-synuclein (αSYN) and inhibits their translation. APP and αSYN can cause neurodegeneration when their aggregates...

Cite
Chen XQ, Barrero CA, Vasquez-Del Carpio R, et al. Posiphen Reduces the Levels of Huntingtin Protein through Translation Suppression. Pharmaceutics. 2021;13(12)doi: 10.3390/pharmaceutics13122109.
Chen, X. Q., Barrero, C. A., Vasquez-Del Carpio, R., Reddy, E. P., Fecchio, C., Merali, S., Deglincerti, A., Fang, C., Rogers, J., & Maccecchini, M. L. (2021). Posiphen Reduces the Levels of Huntingtin Protein through Translation Suppression. Pharmaceutics, 13(12), . https://doi.org/10.3390/pharmaceutics13122109
Chen, Xu-Qiao, et al. "Posiphen Reduces the Levels of Huntingtin Protein through Translation Suppression." Pharmaceutics vol. 13,12 (2021). doi: https://doi.org/10.3390/pharmaceutics13122109
Chen XQ, Barrero CA, Vasquez-Del Carpio R, Reddy EP, Fecchio C, Merali S, Deglincerti A, Fang C, Rogers J, Maccecchini ML. Posiphen Reduces the Levels of Huntingtin Protein through Translation Suppression. Pharmaceutics. 2021 Dec 07;13(12). doi: 10.3390/pharmaceutics13122109. PMID: 34959389.
Copy Download .nbib Format: NLM
Ndfip1 Prevents Rotenone-Induced Neurotoxicity and Upregulation of α-Synuclein in SH-SY5Y Cells.

Frontiers in molecular neuroscience

Liu X, Qu L, Zhang N, Yu X, Xiao Z, Song L, Xie J, Xu H.
PMID: 33469419
Front Mol Neurosci. 2021 Jan 05;13:613404. doi: 10.3389/fnmol.2020.613404. eCollection 2020.

Nedd4 family interacting protein 1 (Ndfip1) is an adaptor of Nedd4-family ubiquitin ligases. Experimental results showed that Ndfip1 had a potential neuroprotective effect in neurology diseases. However, the neuroprotective effect and the underlying mechanisms of Ndfip1 in Parkinson's disease...

Cite
Liu X, Qu L, Zhang N, et al. Ndfip1 Prevents Rotenone-Induced Neurotoxicity and Upregulation of α-Synuclein in SH-SY5Y Cells. Front Mol Neurosci. 2021;13:613404doi: 10.3389/fnmol.2020.613404.
Liu, X., Qu, L., Zhang, N., Yu, X., Xiao, Z., Song, L., Xie, J., & Xu, H. (2020). Ndfip1 Prevents Rotenone-Induced Neurotoxicity and Upregulation of α-Synuclein in SH-SY5Y Cells. Frontiers in molecular neuroscience, 13613404. https://doi.org/10.3389/fnmol.2020.613404
Liu, Xin, et al. "Ndfip1 Prevents Rotenone-Induced Neurotoxicity and Upregulation of α-Synuclein in SH-SY5Y Cells." Frontiers in molecular neuroscience vol. 13 (2020): 613404. doi: https://doi.org/10.3389/fnmol.2020.613404
Liu X, Qu L, Zhang N, Yu X, Xiao Z, Song L, Xie J, Xu H. Ndfip1 Prevents Rotenone-Induced Neurotoxicity and Upregulation of α-Synuclein in SH-SY5Y Cells. Front Mol Neurosci. 2021 Jan 05;13:613404. doi: 10.3389/fnmol.2020.613404. eCollection 2020. PMID: 33469419; PMCID: PMC7813998.
Copy Download .nbib Format: NLM
Parkinson's Disease: The Mitochondria-Iron Link.

Parkinson's disease

Muñoz Y, Carrasco CM, Campos JD, Aguirre P, Núñez MT.
PMID: 27293957
Parkinsons Dis. 2016;2016:7049108. doi: 10.1155/2016/7049108. Epub 2016 May 17.

Mitochondrial dysfunction, iron accumulation, and oxidative damage are conditions often found in damaged brain areas of Parkinson's disease. We propose that a causal link exists between these three events. Mitochondrial dysfunction results not only in increased reactive oxygen species...

Cite
Muñoz Y, Carrasco CM, Campos JD, et al. Parkinson's Disease: The Mitochondria-Iron Link. Parkinsons Dis. 2016;2016:7049108doi: 10.1155/2016/7049108.
Muñoz, Y., Carrasco, C. M., Campos, J. D., Aguirre, P., & Núñez, M. T. (2016). Parkinson's Disease: The Mitochondria-Iron Link. Parkinson's disease, 20167049108. https://doi.org/10.1155/2016/7049108
Muñoz, Yorka, et al. "Parkinson's Disease: The Mitochondria-Iron Link." Parkinson's disease vol. 2016 (2016): 7049108. doi: https://doi.org/10.1155/2016/7049108
Muñoz Y, Carrasco CM, Campos JD, Aguirre P, Núñez MT. Parkinson's Disease: The Mitochondria-Iron Link. Parkinsons Dis. 2016;2016:7049108. doi: 10.1155/2016/7049108. Epub 2016 May 17. PMID: 27293957; PMCID: PMC4886095.
Copy Download .nbib Format: NLM
Posiphen Reduces the Levels of Huntingtin Protein through Translation Suppression.

Pharmaceutics

Chen XQ, Barrero CA, Vasquez-Del Carpio R, Reddy EP, Fecchio C, Merali S, Deglincerti A, Fang C, Rogers J, Maccecchini ML.
PMID: 34959389
Pharmaceutics. 2021 Dec 07;13(12). doi: 10.3390/pharmaceutics13122109.

Posiphen tartrate (Posiphen) is an orally available small molecule that targets a conserved regulatory element in the mRNAs of amyloid precursor protein (APP) and α-synuclein (αSYN) and inhibits their translation. APP and αSYN can cause neurodegeneration when their aggregates...

Cite
Chen XQ, Barrero CA, Vasquez-Del Carpio R, et al. Posiphen Reduces the Levels of Huntingtin Protein through Translation Suppression. Pharmaceutics. 2021;13(12)doi: 10.3390/pharmaceutics13122109.
Chen, X. Q., Barrero, C. A., Vasquez-Del Carpio, R., Reddy, E. P., Fecchio, C., Merali, S., Deglincerti, A., Fang, C., Rogers, J., & Maccecchini, M. L. (2021). Posiphen Reduces the Levels of Huntingtin Protein through Translation Suppression. Pharmaceutics, 13(12), . https://doi.org/10.3390/pharmaceutics13122109
Chen, Xu-Qiao, et al. "Posiphen Reduces the Levels of Huntingtin Protein through Translation Suppression." Pharmaceutics vol. 13,12 (2021). doi: https://doi.org/10.3390/pharmaceutics13122109
Chen XQ, Barrero CA, Vasquez-Del Carpio R, Reddy EP, Fecchio C, Merali S, Deglincerti A, Fang C, Rogers J, Maccecchini ML. Posiphen Reduces the Levels of Huntingtin Protein through Translation Suppression. Pharmaceutics. 2021 Dec 07;13(12). doi: 10.3390/pharmaceutics13122109. PMID: 34959389; PMCID: PMC8708689.
Copy Download .nbib Format: NLM
Inflaming the Brain with Iron.

Antioxidants (Basel, Switzerland)

Urrutia PJ, Bórquez DA, Núñez MT.
PMID: 33419006
Antioxidants (Basel). 2021 Jan 06;10(1). doi: 10.3390/antiox10010061.

Iron accumulation and neuroinflammation are pathological conditions found in several neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD). Iron and inflammation are intertwined in a bidirectional relationship, where iron modifies the inflammatory phenotype of microglia and infiltrating...

Cite
Urrutia PJ, Bórquez DA, Núñez MT. Inflaming the Brain with Iron. Antioxidants (Basel). 2021;10(1)doi: 10.3390/antiox10010061.
Urrutia, P. J., Bórquez, D. A., & Núñez, M. T. (2021). Inflaming the Brain with Iron. Antioxidants (Basel, Switzerland), 10(1), . https://doi.org/10.3390/antiox10010061
Urrutia, Pamela J, et al. "Inflaming the Brain with Iron." Antioxidants (Basel, Switzerland) vol. 10,1 (2021). doi: https://doi.org/10.3390/antiox10010061
Urrutia PJ, Bórquez DA, Núñez MT. Inflaming the Brain with Iron. Antioxidants (Basel). 2021 Jan 06;10(1). doi: 10.3390/antiox10010061. PMID: 33419006; PMCID: PMC7825317.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 12 entries